Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

RGEN Price Correlated With Financials For Repligen

Free historical financial statements for Repligen Corp. See how revenue, income, cash flow, and balance sheet financials have changed over 41 quarters since 2012. Compare with RGEN stock chart to see long term trends.

RGEN Stock Compared to Quarterly

RGEN Income Statement

Revenue, Net:206400000
Revenue Per Share:3.7234
Cost of Goods & Services Sold:82356000
Selling, General & Admin Expense:54300000
Research & Development Expense:12155000
Total Operating Expenses:146400000
Operating Income:60000000
Income Taxes:11967000
Net Income:46964000
Earnings Per Share, Basic:0.85
Shares Outstanding, Basic Avg:55433161

RGEN Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:11834000
Change in Accounts Receiveable:6269000
Net Cash from Operations:23113000
Net Cash from Operations Per Share:0.417
Net Cash from Financing Activities:-12021000
Property, Plant & Equipment Purchases:27204000
Purchases of Businesses, Net of Cash:null
Net Cash from Investing Activities:-28214000
Net Change in Cash & Equivalents:-19174000

RGEN Balance Sheet

Cash and Cash Equivalents:584640000
Accounts Receivable, Net:122435000
Inventories:213775000
Total Current Assets:944789000
Property, Plant & Equipment, Net:147627000
Total Assets:2383824000
Accounts Payable:38280000
Total Short-Term Liabilities:424333000
Total Liabilities:617423000

Data imported from Repligen Corp SEC filings. Check original filings before making any investment decision.